[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334155-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334155-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pd-1pd-l1-immune-checkpoint-blockade-in-breast-cancer-research-insights-and-sensitization-strategies","PD-1/PD-L1 immune checkpoint blockade in breast cancer - research insights and sensitization strategies","","Immunotherapy targeting programmed cell death-1 (PD-1) and PD-L1 immune checkpoints has reshaped treatment paradigms across several cancers, including breast cancer. Combining PD-1/PD-L1 immune checkpoint blockade (ICB) with chemotherapy shows promising efficacy in early and metastatic triple-negative breast cancer, but only a subset achieves durable responses. This review summarizes clinical-trial findings for ICBs, explains mechanisms of PD-L1 expression regulation, highlights emerging biomarker evidence, including tumor-infiltrating lymphocyte traits and spatial distribution, and discusses sensitization strategies to support more personalized treatments.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pd-1pd-l1-immune-checkpoint-blockade-in-breast-cancer-research-insights-and-sensitization-strategies/334155/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pd-1pd-l1-immune-checkpoint-blockade-in-breast-cancer-research-insights-and-sensitization-strategies/334155.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are responders and biomarker selection important for PD-1/PD-L1 therapy in breast cancer?","Question",{"text":63,"@type":64},"Durable responses occur only in a subset of patients. The review emphasizes that identifying responders and optimizing immune drug selection are critical, while reliable biomarkers remain limited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What factors determine the effectiveness of PD-1/PD-L1 immunotherapy?",{"text":68,"@type":64},"Effectiveness depends on tumor-intrinsic factors and extrinsic cell-cell interactions within the tumor microenvironment (TME). The review links ICB outcomes to TME complexity and dynamics.",{"name":70,"@type":61,"acceptedAnswer":71},"Which biomarkers are highlighted as promising for PD-1/PD-L1 therapy?",{"text":72,"@type":64},"The review highlights tumor-infiltrating lymphocytes, focusing on their quantity, immunophenotype, and spatial distribution, as promising biomarkers reflecting TME alterations after treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334155,1790713647,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Jin et al. Molecular Cancer (2024) 23:266 Molecular Cancer  \n[https://doi.org/10.1186/s12943-024-02176-8](https://doi.org/10.1186/s12943-024-02176-8)  \nREVIEW Open Access  \nPD-1/PD-L1 immune checkpoint blockade in breast cancer: research insightsand sensitization strategies  \nMenglei Jin 1,2†, Jun Fang4†, Junwen Peng5†, Xintian Wang6, Ping Xing 1,2, Kunpeng Jia 1,2, Jianming Hu 1,2, Danting Wang 1,2, Yuxin Ding 1,2, Xinyu Wang4, Wenlu Li3* and Zhigang Chen 1,2*  \nAbstract  \nImmunotherapy targeting programmed cell death-1 (PD-1) and PD-L1 immune checkpoints has reshaped treatment paradigms across several cancers, including breast cancer. Combining PD-1/PD-L1 immune checkpoint blockade (ICB) with chemotherapy has shown promising efficacy in both early and metastatic triple-negative breast cancer, although only a subset of patients experiences durable responses. Identifying responders and optimizing immune drug selection are therefore critical. The effectiveness of PD-1/PD-L1 immunotherapy depends on both tumor-intrinsic factors and the extrinsic cell-cell interactions within the tumor microenvironment (TME) . This review systematically summarizes the key findings from clinical trials of ICBs in breast cancer and examines the mechanisms underlying PD-L1 expression regulation. We also highlight recent advances in identifying potential biomarkers for PD-1/PD-L1 therapy and emerging evidence ofTME alterations following treatment. Among these, the quantity, immunophenotype, and spatial distribution of tumor-infiltrating lymphocytes stand out as promising biomarkers. Additionally, we explore strategies to enhance the effectiveness of ICBs in breast cancer, aiming to support the development of personalized treatment approaches tailored to the unique characteristics of each patient’s tumor.  \nKeywords Breast cancer, PD-1/PD-L1, Immune checkpoint blockade, Clinical trials, Biomarkers, Sensitization strategies  \n†Menglei Jin, Jun Fang and Junwen Peng contributed equally to this work.  \n*Correspondence:  \nWenlu Li [wenluli@yahoo.com](wenluli@yahoo.com)[ ](wenluli@yahoo.com)Zhigang Chen[chenzhigang@zju.edu.cn](chenzhigang@zju.edu.cn)  \n1Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China  \n2Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China  \n3Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China  \n4Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China  \n5Department of General Surgery, The First People’s Hospital of Jiande, Hangzhou, China  \n6Department of General Surgery, The Second People’s Hospital of Tongxiang, Jiaxing, Zhejiang, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nJin et al. Molecular Cancer (","cbCaikXhKa8clShi","https://ap.wps.com/l/cbCaikXhKa8clShi","pdf",3574631,22,"English","# Introduction\n# Abstract\n# Keywords\n# Sensitization strategies and biomarker advances","[{\"question\":\"Why are responders and biomarker selection important for PD-1/PD-L1 therapy in breast cancer?\",\"answer\":\"Durable responses occur only in a subset of patients. The review emphasizes that identifying responders and optimizing immune drug selection are critical, while reliable biomarkers remain limited.\"},{\"question\":\"What factors determine the effectiveness of PD-1/PD-L1 immunotherapy?\",\"answer\":\"Effectiveness depends on tumor-intrinsic factors and extrinsic cell-cell interactions within the tumor microenvironment (TME). The review links ICB outcomes to TME complexity and dynamics.\"},{\"question\":\"Which biomarkers are highlighted as promising for PD-1/PD-L1 therapy?\",\"answer\":\"The review highlights tumor-infiltrating lymphocytes, focusing on their quantity, immunophenotype, and spatial distribution, as promising biomarkers reflecting TME alterations after treatment.\"}]","PD-1/PD-L1 immune checkpoint blockade in breast cancer - research insights and sensitization strategies | PDF",1790005523,55]